Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease
- PMID: 1656540
- DOI: 10.1002/syn.890080405
Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease
Abstract
The density of [125I]iodo-cyanopindolol binding to beta-1 and beta-2 adrenergic receptors was studied in post mortem basal ganglia samples of Huntington's chorea and Parkinson's disease patients using autoradiography. Whereas no significant changes were observed in sections from Parkinson's and Huntington's chorea grade 2 patients, a nearly complete loss of beta-1 binding sites was observed in the basal ganglia of Huntington patients at later stages of the disease. The concentration of beta-2 receptors was increased by a factor 2 in the posterior putamen of all choreic cases. These results are consistent with the view that beta-1 receptors are predominantly located on a subpopulation of neurons which degenerate at late stages of Huntington's chorea, while beta-2 receptors are present mainly on glial elements.
Similar articles
-
Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.Synapse. 1993 Nov;15(3):209-20. doi: 10.1002/syn.890150306. Synapse. 1993. PMID: 7904088
-
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.Brain. 2007 Jan;130(Pt 1):222-32. doi: 10.1093/brain/awl332. Epub 2006 Dec 2. Brain. 2007. PMID: 17142832
-
Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia.Synapse. 1991 Feb;7(2):114-22. doi: 10.1002/syn.890070205. Synapse. 1991. PMID: 1672780
-
Recent developments in Parkinson's disease and Huntington's chorea.Int J Neurol. 1976;11(1):17-27. Int J Neurol. 1976. PMID: 138661 Review. No abstract available.
-
The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.Ann Neurol. 1980 May;7(5):406-11. doi: 10.1002/ana.410070503. Ann Neurol. 1980. PMID: 6446874 Review. No abstract available.
Cited by
-
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.Toxins (Basel). 2021 Jul 20;13(7):505. doi: 10.3390/toxins13070505. Toxins (Basel). 2021. PMID: 34357977 Free PMC article.
-
Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.CNS Neurol Disord Drug Targets. 2025;24(2):115-131. doi: 10.2174/0118715273329531240911075309. CNS Neurol Disord Drug Targets. 2025. PMID: 39323347 Review.
-
Activation of beta1-adrenoceptors excites striatal cholinergic interneurons through a cAMP-dependent, protein kinase-independent pathway.J Neurosci. 2003 Jun 15;23(12):5272-82. doi: 10.1523/JNEUROSCI.23-12-05272.2003. J Neurosci. 2003. PMID: 12832552 Free PMC article.
-
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.Pharmacol Biochem Behav. 2012 Jan;100(3):607-15. doi: 10.1016/j.pbb.2011.09.009. Epub 2011 Sep 25. Pharmacol Biochem Behav. 2012. PMID: 21978941 Free PMC article.
-
Adrenergic receptors in the cerebellum of olivopontocerebellar atrophy.J Neural Transm Gen Sect. 1994;96(2):135-42. doi: 10.1007/BF01277935. J Neural Transm Gen Sect. 1994. PMID: 7857596
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical